Article | Published:

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

Nature Medicine volume 18, pages 15031510 (2012) | Download Citation

  • A Corrigendum to this article was published on 06 December 2012

This article has been updated

Abstract

The discovery of potent inhibitors of the BRAF proto-oncogene has revolutionized therapy for melanoma harboring mutations in BRAF, yet NRAS-mutant melanoma remains without an effective therapy. Because direct pharmacological inhibition of the RAS proto-oncogene has thus far been unsuccessful, we explored systems biology approaches to identify synergistic drug combination(s) that can mimic RAS inhibition. Here, leveraging an inducible mouse model of NRAS-mutant melanoma, we show that pharmacological inhibition of mitogen-activated protein kinase kinase (MEK) activates apoptosis but not cell-cycle arrest, which is in contrast to complete genetic neuroblastoma RAS homolog (NRAS) extinction, which triggers both of these effects. Network modeling pinpointed cyclin-dependent kinase 4 (CDK4) as a key driver of this differential phenotype. Accordingly, combined pharmacological inhibition of MEK and CDK4 in vivo led to substantial synergy in therapeutic efficacy. We suggest a gradient model of oncogenic NRAS signaling in which the output is gated, resulting in the decoupling of discrete downstream biological phenotypes as a result of incomplete inhibition. Such a gated signaling model offers a new framework to identify nonobvious coextinction target(s) for combined pharmacological inhibition in NRAS-mutant melanomas.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 20 November 2012

     In the version of this article initially published, the formula to calculate the mutual information matrix, which appears in the last page of the Online Methods, was missing a log multiplier. The error has been corrected in the HTML and PDF versions of the article.

Accessions

References

  1. 1.

    , & Hyperactive Ras in developmental disorders and cancer. Nat. Rev. CancerNatl. Rev. 7, 295–308 (2007).

  2. 2.

    et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4013–4023 (2011).

  3. 3.

    et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).

  4. 4.

    et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989–1000 (2011).

  5. 5.

    et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010).

  6. 6.

    et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. New Engl. J. Med. 367, 107–114 (2012).

  7. 7.

    et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 13, 782–789 (2012).

  8. 8.

    Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 18, 555–567 (2012).

  9. 9.

    et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J. Clin. Oncol. 30, suppl; abstr 8511 (2012).

  10. 10.

    et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431–435 (2010).

  11. 11.

    , , , & RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010).

  12. 12.

    et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209–221 (2010).

  13. 13.

    et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207–215 (2012).

  14. 14.

    et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683–695 (2010).

  15. 15.

    et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724–1730 (2010).

  16. 16.

    , , & Logic-based models for the analysis of cell signaling networks. Biochemistry 49, 3216–3224 (2010).

  17. 17.

    , , , & Bayesian network approach to cell signaling pathway modeling. Sci. STKE 2002, pe38 (2002).

  18. 18.

    et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat. Med 18, 436–440 (2012).

  19. 19.

    et al. Transcriptional gene network inference from a massive dataset elucidates transcriptome organization and gene function. Nucleic Acids Res. 39, 8677–8688 (2011).

  20. 20.

    et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472 (1999).

  21. 21.

    et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13, 1576–1583 (2007).

  22. 22.

    et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006).

  23. 23.

    et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 106, 4519–4524 (2009).

  24. 24.

    et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).

  25. 25.

    et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835–848 (2009).

  26. 26.

    , , & Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res. 69, 1985–1994 (2009).

  27. 27.

    et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).

  28. 28.

    et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427–1438 (2004).

  29. 29.

    Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770–1783 (2006).

  30. 30.

    , & Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. CancerNatl. Rev. 10, 825–841 (2010).

  31. 31.

    et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 107, 14903–14908 (2010).

  32. 32.

    , , & Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res. 22, 785–798 (2009).

  33. 33.

    et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 69, 3042–3051 (2009).

  34. 34.

    et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70, 2264–2273 (2010).

  35. 35.

    et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63–73 (2010).

  36. 36.

    et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 40, 600–608 (2008).

  37. 37.

    et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139–2146 (2008).

  38. 38.

    et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br. J. Cancer 104, 1862–1868 (2011).

  39. 39.

    et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981–1989 (2001).

  40. 40.

    et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27–37 (1996).

  41. 41.

    et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl. Acad. Sci. USA 107, 8352–8356 (2010).

  42. 42.

    Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).

  43. 43.

    et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249–264 (2003).

  44. 44.

    et al. Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles. PLoS Biol. 5, e8 (2007).

  45. 45.

    , & Node centrality in weighted networks: Generalizing degree and shortest paths. Soc. Networks 32, 245–251 (2010).

Download references

Acknowledgements

We thank G. Mills, Y. Lu and N. Shih at the MD Anderson Reverse Phase Protein Array core facility; E. Fox at the Dana-Farber Cancer Institute Microarray core facility; S. Zhou for mouse husbandry; R. DePinho and G. Draetta and members of the laboratory, including S. Quayle, M. Chen, A. Blanchette and J. Kamara, for insightful discussions; R. Kwong for manuscript proofreading; D. Camacho for helping develop the TRAP algorithm; and M. Bar-Eli (University of Texas MD Anderson Cancer Center, Houston, Texas) for the SB-2 cell line. L.N.K. is supported by the Postdoctoral Fellowship (117842-PF-09-261-01-TBG) from the American Cancer Society. J.J.C. is supported by the US National Institutes of Health Director's Pioneer Award Program and the Howard Hughes Medical Institute. This work was supported by funding from the US National Institutes of Health to L.C. (U01 CA141508). L.C. is a recipient of the Abby S. and Howard P. Milstein 2009 Innovation Award for Melanoma and Skin Cancer Research and a CPRIT (Cancer Prevention Research Institute of Texas) Scholar in Cancer Research.

Author information

Affiliations

  1. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

    • Lawrence N Kwong
    • , Huiyun Liu
    • , Shan Jiang
    • , Aliete E Langsdorf
    • , David Jakubosky
    • , Giannicola Genovese
    • , Florian L Muller
    • , Joseph H Jeong
    • , Ryan P Bender
    • , Gerald C Chu
    •  & Lynda Chin
  2. Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    • Lawrence N Kwong
    • , Shan Jiang
    • , Timothy L Helms
    • , Giannicola Genovese
    • , Florian L Muller
    •  & Lynda Chin
  3. Howard Hughes Medical Institute, Department of Biomedical Engineering and Center for BioDynamics, Boston University, Boston, Massachusetts, USA.

    • James C Costello
    •  & James J Collins
  4. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

    • Gerald C Chu
  5. Division of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.

    • Keith T Flaherty
  6. Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.

    • Jennifer A Wargo
  7. Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA.

    • James J Collins
  8. Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    • Lynda Chin

Authors

  1. Search for Lawrence N Kwong in:

  2. Search for James C Costello in:

  3. Search for Huiyun Liu in:

  4. Search for Shan Jiang in:

  5. Search for Timothy L Helms in:

  6. Search for Aliete E Langsdorf in:

  7. Search for David Jakubosky in:

  8. Search for Giannicola Genovese in:

  9. Search for Florian L Muller in:

  10. Search for Joseph H Jeong in:

  11. Search for Ryan P Bender in:

  12. Search for Gerald C Chu in:

  13. Search for Keith T Flaherty in:

  14. Search for Jennifer A Wargo in:

  15. Search for James J Collins in:

  16. Search for Lynda Chin in:

Contributions

L.N.K. performed the majority of experiments described in the manuscript. J.C.C. performed GSEA and TRAP analyses. L.N.K. and J.C.C. jointly generated the remaining statistics. H.L. and T.L.H. helped maintain nude mouse colonies and provided technical assistance in many experiments. S.J. maintained the iNRAS GEM model colony and measured tumor volumes for primary melanomas. A.E.L., D.J. and G.C.C. performed the EVOC work, and the biopsy was supplied by J.A.W. and K.T.F. G.G. and F.L.M. performed some western blotting. J.H.J. generated the iNRAS mouse. R.P.B. assisted in generating the iNRAS time course microarray data. J.J.C. oversaw TRAP and statistical analyses. L.N.K. and L.C. conceived of the study. L.N.K., J.C.C. and L.C. wrote the paper.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Lynda Chin.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–9

Excel files

  1. 1.

    Supplementary Tables

    Supplementary Tables 1–8

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.2941

Further reading